文献速递瓣膜外科主动脉外科

主动脉瓣置换同期升主动脉替换对手术并发症和死亡率的影响

Impact of concomitant replacement of the ascending aorta in patients undergoing aortic valve replacement on operative morbidity and mortality.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该回顾性队列研究经3:1倾向匹配比较孤立主动脉瓣置换(120例)与同期升主动脉替换(40例),发现联合手术显著延长体外循环和主动脉阻断时间及ICU停留,但未增加输血、再探查、房颤、肾衰、卒中、心梗及30天死亡率。

要点

  • 同期升主动脉替换显著延长体外循环和主动脉阻断时间。
  • 联合手术未增加围术期并发症和30天死亡率。
  • 对升主动脉扩张的主动脉瓣置换患者,同期替换安全持久。

核心结论

  • 同期升主动脉替换显著延长体外循环和主动脉阻断时间,但不增加手术并发症和死亡率。
  • 对升主动脉扩张的主动脉瓣置换患者,同期替换升主动脉似乎是最持久且最安全的治疗选择。

研究设计与样本

  • 回顾性分析2009年1月至2020年5月单中心择期孤立主动脉瓣置换及同期升主动脉替换患者,排除感染性心内膜炎或需深低温停循环者。
  • 采用3:1倾向匹配,比较孤立主动脉瓣置换(120例)与主动脉瓣置换+升主动脉替换(40例)。

主要发现

  • 体外循环时间中位数孤立组92.5(75-114)分钟 vs 联合组118.5(104-131)分钟,P < 0.001。
  • 主动脉阻断时间中位数孤立组65.0(51.5-78.5)分钟 vs 联合组84.5(77-94)分钟,P < 0.001。
  • ICU停留时间中位数孤立组1(1-3)天 vs 联合组2(1-6)天,P < 0.01。
  • 术中及术后血制品使用、因出血再探查、术后房颤、急性肾衰竭、卒中、围术期心肌梗死及30天死亡率均无显著差异。

临床怎么用

  • 对主动脉瓣病变合并升主动脉扩张的患者,可考虑同期行升主动脉替换,不增加手术并发症和死亡率。
  • 需注意同期联合手术会延长体外循环和主动脉阻断时间及ICU停留。

局限性

  • 排除感染性心内膜炎及需深低温停循环者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to evaluate the impact of concomitant ascending aortic replacement on operative morbidity and mortality in patients undergoing aortic valve replacement (AVR). METHODS: We retrospectively analysed our institutional database for all patients undergoing elective isolated AVR and AVR with concomitant replacement of the ascending aorta between January 2009 and May 2020. Patients undergoing surgery for infective endocarditis or requiring hypothermic circulatory arrest were excluded. A 3:1 propensity matching was performed for 688 patients to compare isolated AVR (120 patients) with AVR + ascending aortic replacement (40 patients). RESULTS: There were significant differences in median cardiopulmonary bypass (CPB) time [92.5 (75-114) vs 118.5 (104-131) min; P < 0.001], median aortic cross-clamp time [65.0 (51.5-78.5) vs 84.5 (77-94) min; P < 0.001] and median intensive care unit stay [1 (1-3) vs 2 (1-6) days; P < 0.01]. There was no significant difference in the use of intraoperative and postoperative blood products, re-exploration for bleeding, postoperative atrial fibrillation, acute renal failure, incidence of stroke, perioperative myocardial infarction and 30-day mortality. CONCLUSIONS: Concomitant replacement of the ascending aorta significantly prolongs CPB and aortic clamp times but does not increase operative morbidity and mortality. Therefore, replacement of a dilated ascending aorta appears to be the most durable and safest treatment option in patients undergoing AVR with an aneurysmatic ascending aorta.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Winkler A, Puiu P, Krombholz-Reindl P, et al. Impact of concomitant replacement of the ascending aorta in patients undergoing aortic valve replacement on operative morbidity and mortality. Eur J Cardiothorac Surg. 2022. PMID: 34626175. doi:10.1093/ejcts/ezab420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。